Results 91 to 100 of about 21,888 (191)
Current Management of In-Stent Restenosis
In-stent restenosis (ISR) remains the primary cause of target lesion failure following percutaneous coronary intervention (PCI), resulting in 10-year incidences of target lesion revascularization at a rate of approximately 20%. The treatment of ISR is challenging due to its inherent propensity for recurrence and varying susceptibility to available ...
Giacoppo, Daniele +2 more
openaire +2 more sources
The Role Of Inflammation In Stent Restenosis More Than 1 Year Afetr Drug Eluting Stent Implantation
Background: In stent restenosis (ISR) following endovascular interventions is the main limitation of their long-term success. Despite advances have been made during recent years to decrease restenosis, it remains a challenging clinical problem.The aim of
Hasan Shemirani +2 more
doaj
BACKGROUND: The association between epicardial fat and coronary in-stent restenosis hasnot been evaluated. The objective of the present study was to evaluate the relationship ofechocardiographic epicardial fat thickness (EFT) with restenosis in drug ...
Fariborz Nikaeen +4 more
doaj
Prediction of Coronary Artery Restenosis in Patients Undergoing Angioplasty
BACKGROUND AND OBJECTIVE: Coronary artery restenosis following angioplasty may lead to major unwanted cardiac events. This is one of the most important concerns of cardiologists.
F Ebrahimzadeh +3 more
doaj
Recurrent In-Stent Restenosis Treated With a Novel Technique: The Double-DCB Technique. [PDF]
Ang AS +4 more
europepmc +1 more source
CTRP12: A Novel Biomarker in Predicting In-Stent Restenosis Occurrence. [PDF]
Nie Y, Song W.
europepmc +1 more source
Methodological Considerations in Evaluating CTRP12 as a Biomarker for In-Stent Restenosis. [PDF]
Khattak S, Rayyan SM, Khan SH.
europepmc +1 more source
Glucocorticoid Therapy for Recurrent In-Stent Restenosis: A Prospective Explorative Case Series. [PDF]
Yu M +7 more
europepmc +1 more source

